Developing precision medicines for kidney diseases

Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.

Read More

News & HIGHLIGHTs

October 5, 2020

Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing

Read More

October 5, 2020

Download the latest Chinook Corporate Presentation

Read More

Atrasentan Update

We plan to initiate a Phase 3 clinical trial (ALIGN) of atrasentan in early 2021 for biomarker-selected patients with IgA Nephropathy at high risk for progressive kidney function loss.

Read More

Pipeline

Advancing a pipeline of precision medicines for kidney diseases.

Our lead pipeline candidates target rare, severe kidney disorders with few currently approved therapies.

pipeline

mobile pipeline

Learn More